Drug
Solabegron clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2006 (3)
| Year | Studies |
|---|---|
| 2006 | 3 |
| 2007 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses solabegron is read from its arms, and is right about nine times in ten.
Testing it · 5
- A Study To Test The Interaction of Two Medications for Treatment of Overactive BladderCompletedPhase 1GlaxoSmithKlineNCT00501267Written as solabegron and oxybutynin
- A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)CompletedPhase 2GlaxoSmithKlineNCT00394186Written as GW427353
- Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder SymptomsCompletedPhase 2GlaxoSmithKlineNCT00343486Written as Solabegron
- A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy VolunteersCompletedPhase 1GlaxoSmithKlineNCT00401479Written as Solabegron (GW427353)
- A Two-Part Study to Determine: Best Medication Formulation and Food EffectCompletedPhase 1GlaxoSmithKlineNCT00427596Written as Solabegron
Codes
What other systems call solabegron · ClinicalTrials.gg INT005176
- MeSH (NLM) C523977solabegronConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 55P6YH9O6NSOLABEGRONConfirmed FDA, NLM
- NCI Thesaurus C96754SolabegronOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C523977 | solabegron | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 55P6YH9O6N | SOLABEGRON | Confirmed FDA, NLM |
| NCI Thesaurus | C96754 | Solabegron | One source FDA |
Also registered as solabegron hydrochloride (UNII GU14FR8D4A).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.